ArticleThe Journal of experimental medicine2021
TRPA1: An asthma target with a zing.
Article in The Journal of experimental medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
- Mechanically induced dysregulation of calcium homeostasis: a molecular linchpin in asthmatic pathogenesis.European journal of medical research · 2025Review
- The role of TRPA1 in lung cancer.Translational lung cancer research · 2025Review
- Mechanisms and Consequences of Variable TRPA1 Expression by Airway Epithelial Cells: Effects ofEnvironmental health perspectives · 2023Article
- TRPA1 as a potential factor and drug target in scleroderma: dermal fibrosis and alternative macrophage activation are attenuated in TRPA1-deficient mice in bleomycin-induced experimental model of scleroderma.Arthritis research & therapy · 2023Article
- Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists May Provide a Superior Treatment for Pain and Migraine.ACS medicinal chemistry letters · 2021Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Asthma therapy has advanced remarkably; however, a significant number of patients respond poorly to current interventions. Balestrini et al. (2021. J. Exp. Med.https://doi.org/10.1084/jem.20201637) advance the concept that sensory nerves control inflammation in asthma, demonstrating that a novel inhibitor of TRPA1, a nerve receptor for irritants and reactive endogenous mediators, suppresses inflammation and airway smooth muscle contraction in several preclinical species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.